论文部分内容阅读
阐述耐多药结核病人(MDR-TB),即至少对异烟肼和利福平耐药,初治后复发或失败后接受WHO推荐的标准复治方案病人转归的有关资料很少。在这一病例系列中,我们检查了常规样本,42例已记录为MDR-TB并已接受WHO标准复治方案(2SHRZE/1HRZE/5H_3R_3E_3)的复发或失败病人的治疗结果。一例病人在治疗的最后一个月内死亡;其余41例病人完成复治方案。42例病人中,14例(33％)完成治疗时痰涂片阴性。MDR-TB用WHO复治方案治愈的病人比例与结核病无化疗的时代结果相似。
There is little information on MDR-TB, which is resistant to at least isoniazid and rifampicin, following standard regimen recommended by WHO after relapse or failure after initial treatment. In this case series, we examined routine samples and 42 patients who had been documented as MDR-TB and who had undergone treatment in patients with recurrent or failed WHO standard regimen (2SHRZE / 1HRZE / 5H_3R_3E_3). One patient died within the last month of treatment; the remaining 41 patients completed the regimen. Of the 42 patients, sputum smear was negative in 14 (33%) of the patients on completion of treatment. The proportion of MDR-TB patients cured by the WHO retreatment program is similar to that of the non-chemotherapy era of tuberculosis.